PAP vaccines for prostate cancer


The invention relates to peptide analogues from prostate acidic phosphatase (PAP) and their use as vaccines for prostate cancer. In particular, the analogue includes the change of alanine to leucine at position 115 of PAP which has been found to be particular advantageous.

The mutation at position 115 has been unexpectedly found to produce enhanced immune responses. The invention provides a polypeptide comprising a sequence which has HLA-A2 binding activity.

This invention will allow us to develop a vaccine therapies based on the 42mer PAP sequence to enable prostate cancer to be treated.

Benefits and applications

  • Ability to develop PAP specific vaccines for prostate cancer patients and increase the success rate of the therapy.

Contact details

Professor Robert Rees
The John Van Geest Cancer Research Centre